# An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)

Source: https://onco.cc/trials/nct05112965/  
OnCo record `nct05112965` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Atezolizumab, Bevacizumab, Pemetrexed and Enzalutamide in advanced solid tumours, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) is a phase 3 interventional study registered as NCT05112965 by Hoffmann-La Roche, with 49 participants enrolled, started 2021-12-01 and due to reach its primary completion in 2027-06-30. Interventions recorded: Atezolizumab, Bevacizumab, Pemetrexed, Paclitaxel and Enzalutamide.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05112965
- Phase: 3
- Setting: An Open-Label, Multicenter Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
- Sponsor: Hoffmann-La Roche
- Enrolled: 49

## Sources

- ClinicalTrials.gov NCT05112965: https://clinicaltrials.gov/study/NCT05112965

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Atezolizumab](https://onco.cc/drugs/atezolizumab/), [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Enzalutamide](https://onco.cc/drugs/enzalutamide/), [Pemetrexed](https://onco.cc/drugs/pemetrexed/)
- companies: [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/)

---
JSON: https://onco.cc/api/v1/entities/nct05112965.json